Immunogen to acquire Boundless Bio for $1.1 billion

au.investing.com

Boundless Bio Inc. announced a definitive agreement to be acquired by Immunogen Inc. for approximately $1.1 billion. The deal, announced Monday, April 13, 2026, will see Immunogen acquire all outstanding shares of Boundless Bio for $12.25 per share in cash. This acquisition aims to enhance Immunogen's oncology pipeline with Boundless Bio's novel therapies.


With a significance score of 1.4, this news ranks in the top 41% of today's 32315 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Immunogen to acquire Boundless Bio for $1.1 billion | News Minimalist